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Abstract. The recent Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) trial
reported a reduction in child mortality following biannual azithromycin mass drug administration (MDA). Here, we in-
vestigate the financial costs and cost-effectiveness from the health provider perspective of azithromycin MDA at the
MORDOR-Malawi study site. During MORDOR, a cluster-randomized trial involving biannual azithromycin MDA or pla-
cebo tochildren aged1–59months, fieldwork-related costswere collected, includingpersonnel, transport, consumables,
overheads, training, andsupervision.Mortality rates in azithromycin- andplacebo-treatedclusterswerecalculatedoverall
and for the five health zones of Mangochi district. These were used to estimate the number needed to treat to avert one
death and the costs per death and disability-adjusted life year (DALY) averted. The cost per dose of MDA was $0.74
overall, varying between $0.63 and $0.94 in the five zones. Overall, the number needed to treat to avert one death was
1,213 children; the cost per death averted was $898.47, and the cost per DALY averted was $9.98. In the three zones
wheremortality was lower in azithromycin-treated clusters, the number needed to treat to avert one death, cost per death
averted, and cost per DALY averted, respectively, were as follows: 3,070, $2,899.24, and $32.31 in Monkey Bay zone;
1,530, $1,214.42, and $13.49 in Chilipa zone; and 344, $217.98, and $2.42 in Namwera zone. This study is a preliminary
cost-effectiveness analysis that indicates azithromycin MDA for reducing child mortality has the potential to be highly
cost-effective in some settings in Malawi, but the reasons for geographical variation in effectiveness require further
investigation.
INTRODUCTION
Azithromycin mass drug administration (MDA) is a key part
of the global campaign to eliminate blinding trachoma.1 Re-
search alongside trachoma programs has indicated a benefi-
cial effect of azithromycin MDA on child morbidity indicators,2–6
and increasing evidence suggests this may include a reduction
in child mortality.7,8
Despite accelerating reductions in child mortality over the
past twodecades, progress is not uniform,withmore thanone
in 10 children still dying before their fifth birthday in six coun-
tries, five of them in sub-Saharan Africa.9 At current annual
rates of reduction in child mortality, many countries will not
meet the Sustainable Development Goals for reduction in
child mortality by 2030, with the 2015 Millennium Develop-
mentGoal for childmortality not likely tobemetglobally before
2026.9 Socioeconomic progress and improvements in health
systems are key to long-term progress in reducing child mor-
tality. However, in the short term, practical, cost-effective in-
terventions to reduce child mortality are of particular interest.
The MORDOR trial, investigating the effect of biannual azi-
thromycin MDA to children aged 1–59 months on child mor-
tality in Malawi, Niger, and Tanzania, reported 14% lower
mortality in azithromycin- compared to placebo-treated
communities.8 The effect was not uniform, with mortality re-
duction of 6% inMalawi, 18% inNiger, and 3% in Tanzania. In
addition, the effect differed significantly by age-group. Such
heterogeneity raises important questions about who should
be targeted and where, if wider country campaigns of azi-
thromycinMDA to reduce childmortality are to be considered.
Cost-effectivenesswill play a key role in suchpolicy decisions.
As cost data were not collected uniformly at the three
MORDOR study sites, this study reports child mortality in
different geographical areas of the MORDOR trial in Malawi
and the associated financial costs and cost-effectiveness of
the intervention from the health provider perspective.
METHODS
MORDOR trial. The MORDOR trial in Malawi was con-
ducted in Mangochi district, one of the poorer districts in
Malawi, with associated high birth rates, low literacy, and little
formal employment.10 Mangochi district is shown on the map
(Figure 2). The MORDOR trial methodology has been report-
ed elsewhere.8 Briefly, MORDOR used a cluster-randomized,
placebo-controlled trial design to assess the effects of bi-
annual single-dose azithromycin MDA onmortality in children
aged 1–59 months.
Clusters were defined as the catchment areas of health sur-
veillance assistants (HSAs), which have approximately a total
populationof1,000.Thestudy includedhouse-to-housevisits for
a total of four treatment rounds and five census visits between
March 2015 and June 2017. The study cohort was updated bi-
annually, as each census identified deaths as well as new births
and migrations into or out of the study area. The MORDOR trial
included 334 clusters that were randomly assigned to either the
main mortality study (304 clusters) or for the assessment of
morbidity outcomes (30 clusters). All clusters met the same in-
clusion criteria and were identified from a pre-baseline census.
The cost-effectiveness analyses include all 334 clusters. Man-
gochi district is divided into five zones for health administration
purposes. MORDOR fieldwork and the collection of cost data
were organized by the five distinct geographical zones (Man-
gochi, Namwera, Chilipa, Monkey Bay, and Makanjira).
Intervention. Treatment was administered as 20 mg/kg
azithromycin syrupor an equivalent volumeof placebo. Young
children were weighed to determine dose, and those old
enough to stand were measured and given an approximate
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dose based on their height. Mass drug administration was
performed by HSAs in their own communities with assistance
from village volunteers and MORDOR field-workers, who
also recorded the data using tablet devices. Adverse event
reporting was encouraged for events occurring within 7 days
of the MDA via the HSA to the study team.
Randomization and blinding. The study drug manufac-
turer (Pfizer Inc., New York, NY) labeled medicine bottles with
eight letters corresponding to azithromycin and eight to pla-
cebo to reduce risks of unblinding. Study clusters were ran-
domly assigned to a drug letter by the study statistician using
the statistical package R (the R Foundation for Statistical
Computing, Vienna, Austria). All field and laboratory staff,
supervisors, data managers, and participants were blind to
the treatment code until after all fieldwork was complete.
Outcomes. The primary prespecified outcome for this
study was the cost-effectiveness of azithromycin MDA at the
MORDOR-Malawi study site. The secondary outcome was a
comparison of the differences in cost-effectiveness of azi-
thromycinMDAby health zone inMangochi district. The study
was designed to assess cost-effectiveness from the perspec-
tive of service providers and not from a societal perspective.
Cost data collection. Cost data were collected at the 12-
month follow-up visit and included personnel, transport,
consumables, overheads, training, and supervision. Details
of sources of cost data are provided in Table 1. Efforts were
made to exclude costs related solely to research, such as the
electronic capture of census and treatment data. All daily
fieldwork costs were recorded and cross-checked with
budgets and funds released by the MORDOR trial finance
officer in coordination with the District Environmental Health
Officer. Costs were collected in Malawian Kwacha (MWK)
and converted to U.S. dollars ($) at the exchange rate of
MWK700 = $1.00, the commonly used exchange rate in
Malawi in 2016, where U.S. dollars are often used for major
purchases. The value of the Malawian kwacha fluctuates
significantly on the international market, and the exact ex-
change rate fluctuated above and below the value used for
this study during the 12-month follow-up visit for MORDOR
fieldwork between March and June 2016. All costs presented
in this study are in 2016 USD. There were no missing cost data
as costs were proactively captured during the fieldwork from
budgets and receipts.
Personnel costs included per diems for HSAs, village vol-
unteers, drivers, MORDOR field-workers, and supervisors.
Salary costs were not included for themain analysis, although
HSA salaries were included in a subsequent sensitivity anal-
ysis. Training costs were included for HSAs to conduct the
MDA; separate training costs for field-workers specifically on
the use of tablet devices were excluded. Morbidity assess-
ment costs for field-workers collecting samples and labora-
tory staff working on research activities were excluded.
Vehicle depreciation was calculated daily for twoMORDOR
vehicles by dividing the capital cost of the new vehicles by
their 10-year life expectancy multiplied by 345, an assumed
number of working days per year. Fuel costs were taken from
the fuel receipts used specifically for the fieldwork in each
zone. Additional transport costs, including bicycle and boat
taxis, were included as required.
Azithromycin and placebo suspension were donated by
Pfizer, so no costs were included for study drug in the main
analysis, although the value of azithromycin was included in
a sensitivity analysis. Overheads included rental costs for
office and storage space in two locations and associated
security, utilities, and upkeep costs. Supervision costs were
mainly related to the MORDOR trial supervisors; zonal en-
vironmental health officer’s (EHO’s) costs were included to
attend trainings.
Cost-effectiveness calculations. Total costs were sum-
med for each of the five zones of Mangochi district. The cost
per treatment in each zone and overall was calculated using
the total number of treatments distributed at the 12-month
follow-up visit. Mortality rates per 1,000 person-years were
calculated for azithromycin- and placebo-treated clusters
using the total deaths and person-years of follow-up over the
full 2 years and four intercensal periods of the MORDOR trial.
The number needed to treat to avert one deathwas calculated
from the rate difference between azithromycin and placebo
clusters. The cost per death averted was then calculated by
zone and overall using the number needed to treat and cost
per treatment. Cost per disability-adjusted life year (DALY)
averted was also calculated from years of life lost in the study
using the mean age of mortality of children in the study area
and WHO standard life tables with no age weighting or time
discounting.11,12
A lifetime time horizon was used for this study to capture all
effects associated with a round of azithromycin MDA, as op-
posed to assuming, in effect, that for lives saved during the
intervention, those individuals would die instantly at the end of
any shorter follow-up period. The evidence available to date
regarding the effect of azithromycin MDA on child mortality
does not indicate any reduction in effect with subsequent
rounds of treatment. Indeed, the aggregate efficacy of azi-
thromycin as compared with placebo tended to increase with
each progressive round of treatment in the MORDOR trial.8 In
addition, most of the protective effect of azithromycin MDA
occurred in the 3 months after distribution, so this study as-
sumed that each biannual MDA has an equal and indepen-
dent effect on mortality.13
Cost-effectiveness of the intervention was compared with
the WHO willingness-to-pay thresholds, specifically the esti-
mate that an intervention costing less than three times the
national annual GDP per capita per DALY avoided, may be
FIGURE 1. Breakdown of mass drug administration costs by broad
category. This figure appears in color at www.ajtmh.org.
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considered cost-effective, whereas one costing less than the
national annual GDP per capita may be considered highly
cost-effective.14 The WHO willingness-to-pay criteria applied
toMalawi in 2016, with GDP per capita of $316, indicate that a
cost-effective intervention would cost less than $948 per
DALY averted and a highly cost-effective intervention would
cost less than $316 per DALY averted.15
Sensitivity analyseswereconducted:firstly, adding thevalueof
azithromycinusing themedianpriceestimated for thebuyerusing
theWHOInternationalProductPriceGuideand,secondly, adding
both the value of azithromycin and the salaried time of HSAs.16
Ethical approval. Approval for the MORDOR trial was
obtained from the College of Medicine, University of Malawi;
the London School of Hygiene and Tropical Medicine; and the
UCSF Committee on Human Research. Oral informed con-
sent was obtained from the guardians of participants. There
were no incentives for participation.
RESULTS
The baseline characteristics of clusters and study partici-
pants were similar between placebo and azithromycin arms at
baseline, as shown inTable 2. Thecosts for activities related to
the MDA varied by zone and overall and are listed in Table 3.
The least costly zone for MDA was Namwera, costing $0.63
per dose distributed, slightly cheaper than Mangochi zone at
$0.66. The most expensive zone was Monkey Bay, costing
$0.94 per dose distributed. The mean cost per dose admin-
istered overall zones was $0.74.
A breakdown of costs by broad category is shown in
Figure 1. The highest proportion of costs (41%) was for per-
sonnel associated with conducting the MDA, followed by
transport (30%), overheads (12%), supervision (10%), and
training (7%).
TABLE 1
Sources of cost data
Costs How data were collected/costs estimated*
Training
Environmental health officers’ (EHOs) phone
credit, fuel, and allowance
Distributed to EHOs to attend training and make fieldwork supervisory visits
(between $34.29 and $142.86 for each of the five zones depending on size,
accessibility, and number of EHOs)
Health surveillance assistants’ (HSAs) allowance As provided to each HSA ($17.86 each)
HSAs’ transport Provided to HSAs traveling long distances to attend training ($2.86 per HSA)
Refreshments Actual expenditure for training (between $34.29 and $100.00)
Hall hire (health center or teacher training hall) Actual expenditure (between $8.57 and $10.00 per day)
Personnel
HSAs’ per diem Paid as agreed with the district ddministration ($3.57 per day for 5 days for a total of
$17.86 per HSA); for the sensitivity analysis, each HSA salary was included for the
allocated 1 week of work ($14.29 per HSA)
Volunteers’ per diem Paid as agreed with the district ddministration ($2.14 per day for 5 days for a total of
$10.71 per volunteer in each community)
MORDOR field-workers’ pay/allowances Local enumerators staying at homepaid $2.86 per day for 5 days for a total of $14.29
per community. Enumerators staying away from home paid $5.00 per day
including per diem.
Field-worker accommodation Actual expenditure for field-workers not able to return home at night (rooms costing
between $2.86 and $6.43 per night)
Transport
Vehicle depreciation 2 Toyota LandCruiser vehicles costing $60,000 each, with life expectancy of 10
years, assuming 345 working days per year ($17.39 per day per vehicle)
Fuel Actual expenditure for fieldwork (between $1,721.56 and $2,752.24 per zone)
Boat fare Actual expenditure forfieldwork (between$0.00and$28.57per zone, required toget
to some remote communities without road access)
Bicycle fare Actual expenditure for fieldwork ($1.43 per day for 3 days for one HSA to reach
remote community)
Consumables
Study drug No cost for donated drug; for the sensitivity analysis, cost of azithromycinwas taken
from theWHO InternationalProductPriceGuide for 2015 ($0.94per 30mLbottleof
syrup, with three doses per bottle, as allocated for fieldwork)
Waste bags Actual expenditure for fieldwork ($28.57 per zone)
Overheads
Office and storage space rent Rental cost for twoofficesandstoragespaceduring thefieldwork ($1,128.57/month)
Office security and upkeep Security andupkeepcosts for rentedpremisesduring the fieldwork ($102.86/month)
Office utilities Utilities for rented premises during the fieldwork ($205.71/month)
Supervision
MORDOR staff per diems, accommodation, and
lunch allowances
2–3 staff plus drivers ($14.29 per diem when staying away from Mangochi town;
rooms costing between $4.29 and $8.57 per night; and lunch allowance of $3.57
provided every day)
* All costs were measured during the 12-month follow-up round of MORDOR activities.
TABLE 2
Baseline characteristics of study clusters and participants
Placebo Azithromycin
Number of clusters 167 167
Number of children enrolled 42,825 43,105
Number of children per cluster 286 (SD: 133) 285 (SD: 127)
Gender, male (%) 50.0 50.0
Age-group (%)
1–11 months 18.7 18.6
12–59 months 81.3 81.4
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The mortality rates by zone for placebo- and azithromycin-
treated clusters and calculation of the rate difference between
treatment arms are shown in Table 4. Study clusters are
plotted in Figure 2, indicating the mortality rate difference in
azithromycin and placebo arms by zone.
Overall, the number needed to treat with azithromycin
MDA to avert one death was 1,213 children, the cost per
death averted was $898.47, and the cost per DALY averted
was $9.98 (Table 4). The cost per DALY averted would
indicate this intervention has the potential to be highly
TABLE 3
Itemized costs for MDA by zone
Cost (USD)
Monkey bay Chilipa Makanjira Namwera Mangochi Total
Training
Environmental health officers (phone
credit, fuel, and allowance)
34.29 34.29 114.29 85.71 142.86 411.43
Health surveillance assistants’ (HSAs)
allowance
263.57 771.43 263.57 457.14 708.57 2,464.28
HSAs’ transport 57.14 42.86 28.57 57.14 42.86 228.57
Refreshments 34.29 54.29 43.57 67.14 100.00 299.29
Hall hire (health center or teacher
training hall)
8.57 17.14 17.14 17.14 20.00 80.00
Personnel
HSAs’ per diem 732.14 964.29 732.14 1,535.71 2,214.29 6,178.57
Volunteers’ per diem 439.29 578.57 439.29 921.43 1,328.57 3,707.14
MORDOR field-workers’ pay plus
allowances
1,121.43 1,191.43 1,178.57 1,755.71 1,645.71 6,892.86
Field-worker accommodation 650.00 1,041.43 640.71 900.00 855.00 4,087.14
Transport
Vehicle depreciation 660.87 660.87 660.87 904.35 904.35 3,791.33
Fuel 2,421.87 2,305.27 2,043.78 1,721.56 2,752.24 11,244.73
Boat fare 22.86 0.00 28.57 0.00 0.00 51.43
Bicycle fare 4.29 0.00 0.00 0.00 0.00 4.29
Consumables
Study drug 0.00 0.00 0.00 0.00 0.00 0.00
Waste bags 28.57 28.57 28.57 28.57 28.57 142.86
Overheads
Office and storage space rent 846.43 846.43 846.43 1,128.57 1,128.57 4,796.43
Office security and upkeep 77.14 77.14 77.14 102.86 102.86 437.14
Office utilities 154.29 154.29 154.29 205.71 205.71 874.29
Supervision
MORDOR staff per diems,
accommodation, and lunch
allowances
1,228.57 257.14 930.00 1,796.43 542.86 4,755.00
Total cost 8,785.60 9,025.43 8,227.51 11,685.20 12,723.02 50,446.77
Number of children treated at the
12-month follow-up
9,304 11,369 9,794 18,451 19,197 68,115
Cost per treatment 0.94 0.79 0.84 0.63 0.66 0.74
TABLE 4
Mortality rate by treatment arm and cost-effectiveness by zone
Zone Monkey Bay Chilipa Makanjira Namwera Mangochi Total
Cost/treatment (USD) 0.94 0.79 0.84 0.63 0.66 0.74
Person-years in placebo clusters
(thousands)
7.58 12.28 10.08 18.05 18.94 66.93
Deaths in placebo clusters 53 134 89 191 153 620
Mortality rate in placebo
clusters (deaths per 1,000
person-years, 95% CI)
6.99 (5.34–9.15) 10.91 (9.21–12.93) 8.83 (7.18–10.87) 10.58 (9.18–12.19) 8.08 (6.89–9.46) 9.26 (8.56–10.02)
Person-years in azithro clusters
(thousands)
10.96 11.60 9.33 17.59 17.36 66.84
Deaths in azithro clusters 73 119 87 135 150 564
Mortality rate in azithro
clusters (deaths per 1,000
person-years, 95% CI)
6.66 (5.30–8.38) 10.26 (8.57–12.28) 9.32 (7.56–11.50) 7.67 (6.48–9.08) 8.64 (7.36–10.14) 8.44 (7.77–9.16)
Rate difference (deaths per
1,000 person-years)
0.33 0.65 −0.50 2.91 −0.57 0.82
Number needed to treat to
avert one death
3,070 1,530 – 344 – 1,213
Cost per death averted (USD) 2,899.24 1,214.42 – 217.98 – 898.47
Cost per DALY averted (USD) 32.21 13.49 2.42 9.98
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cost-effective according to the WHO willingness-to-pay
criteria (less than the GDP per capita of $316). The greatest
effect was in the Namwera zone, with the number needed
to treat as 344, cost per death averted of $217.98, and cost
per DALY averted of $2.42. In two zones, Makanjira and
Mangochi, the mortality rate estimate was higher in azi-
thromycin- than placebo-treated clusters, so a figure for
cost per death averted could not be computed for these
zones.
Sensitivity analyses are shown in Table 5. With the ad-
dition of the cost of azithromycin, the cost per death averted
overall increased to $1,278.59 and the cost per DALY
averted to $14.21.With thecostofHSAsalaries for theduration
of the work also included, the cost per death averted further
increased to $1,366.63 and the cost per DALY averted to
$15.18.
DISCUSSION
This study estimated the cost-effectiveness of azithromycin
MDA in the MORDOR trial in Malawi and compared cost-
effectiveness by geographical zone in the intervention district.
The cost per treatment distributed overall was $0.74, and the
cost per death averted was $898.47. The cost per treat-
ment delivered varied by up to 50% between zones. Cost-
effectiveness varied considerably by zone; indeed, in two
zones, the mortality rate was higher in azithromycin-treated
than placebo-treated clusters. In the zones where mortality
FIGURE 2. Mortality rate difference by zone between placebo- and azithromycin-treated clusters (deaths per 1,000 person-years); negative rate
difference indicates higher mortality in azithromycin- than placebo-treated clusters.
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was lower in azithromycin-treated clusters, cost per death
averted varied from $217.98 to $2,899.24.
The MORDOR trial was not powered to identify a mortality
difference at any single site, but using the effect estimate of
mortality and related cost-effectiveness, under $1,000 per
death averted is comparable to recommended inter-
ventions for reducing child mortality, such as integrated
management of childhood illness17 and seasonal malaria
chemoprophylaxis.18
Azithromycin MDA has mostly been conducted by country
programs for the control of trachoma, with the estimated
costs varying considerably, from $0.50 or less per person
treated19–21 to $1.50 or more.22,23 Other MDA programs in
sub-Saharan Africa report generally similar costs: a system-
atic review of lymphatic filariasis MDA programs between
2000 and 2014 reported mean financial cost per treatment of
$0.46 (adjusted to 2014USD), mean economic cost excluding
donated drug of $0.56, and economic cost including donated
drugvalueof $1.32.24 Variation inMDAcostsbycountrywill be
influenced considerably by the costs for staff involved, such
as the use of volunteers or health workers. The costs for
treatment of children only, as in MORDOR, as opposed to
whole community MDA, would be expected to increase as
more time will be required to identify eligible individuals. In
addition, as fewer treatments are distributed when targeting
children only, economies of scale are less, which may also
increase the cost per treatment.
The largest component of the cost of the MDA was personnel
costs, followedby transport. Personnel costs havebeen reported
as themaindriverof azithromycinMDAcosts inother studies.21,22
One of these studies also found transport to contribute the sec-
ond highest costs22, but the other study, in relatively accessible
areas of the Gambia, found transport to not contribute a major
share of costs.21 It is expected that these costs will vary consid-
erably by geographical location and country.
The two main components of personnel costs were HSAs’
and MORDOR field-workers’ per diems. Health surveillance
assistants collect a monthly salary, the costs of which were
included in a sensitivity analysis, and receive per diems for any
additional activities required of them beyond their few days
rostered work at a nearby health center; this includes gov-
ernment campaigns, such as azithromycinMDA for trachoma,
and interventions with other development partners. The per
diems vary considerably; those recorded for this study were
slightly higher than those paid by the government and signif-
icantly lower than those paid by other organizations.
MORDOR field-worker costs were included because of the
key role these staff played in the context of the MORDOR trial
supporting the HSAs with the MDA, although they were also
tasked to update the census and record all treatments dis-
tributed. These exact costs would not be required for a gov-
ernment MDA program, although additional support with
logistics would be needed from district and national health
staff. The time spent during the MDA to complete census is
also likely to have slowed the MDA fieldwork and increased
costs. The level of supervision included in this analysis was
believed to be similar to that which would be performed by
EHOs for a government program; the MORDOR trial supervi-
sors’ per diems and other support costs similar to the allow-
ance and transport costs required for supervision during a
government campaign.
Training costs accounted for 7% of the total MDA costs.
These may be reduced slightly with repeated program distri-
butions although some refresher training would usually be
recommended. Capital costs for setting up the program were
converted to ongoing running costs, for example, by including
a daily depreciation cost for vehicles rather than front-loading
the initial capital cost. This was performed to provide a simple
estimate of the financial costs for a program to provide the
intervention.
Interpretation of the findings of this study, providing the first
estimates of cost-effectiveness from the MORDOR trial, must
consider that it was designed to assess costs from the per-
spective of the health provider. Costs of donated drug were
excluded, although a sensitivity analysis was performed,
which indicated a potential increase in cost per treatment of
42%when the value of azithromycin was included and a 53%
increase when both azithromycin and HSA salaries were in-
cluded. Additional economic indicators associated with an
analysis from the societal perspective, such as opportunity
costs, have not been considered in this study.
The analysis in this study will be relevant to Malawi with
its current level of health system and health programs in
place, termed intervention mix constrained cost-effectiveness
analysis.25 This evaluates the cost-effectiveness of addi-
tional interventions (in this case azithromycin MDA) with re-
spect to theexisting set of interventions, including interventions
improving childmortality that may ormay not have overlapping
benefits with azithromycin MDA. Indeed, many health inter-
ventions are likely to interact with azithromycin MDA in terms
of effect on child health, and therefore, in areas with improved
health access and interventions, azithromycin is likely to pro-
vide lesser additional benefit.
To attempt to isolate the cost-effectiveness independent of
other health interventions in a study area, termed generalized
cost-effectiveness analysis, requires the analyst to consider
the future effects if all health sector resources could be
reallocated25 and is beyond the scope of this study.
TABLE 5
Sensitivity analyses for cost-effectiveness including cost of azithromycin and HSAs’ salaries
Zone Monkey Bay Chilipa Makanjira Namwera Mangochi Total
Including the cost of azithromycin
Cost/treatment (USD) 1.26 1.11 1.15 0.95 0.98 1.05
Cost per death averted (USD) 3,861.27 1,693.74 – 325.82 – 1,278.59
Cost per DALY averted (USD) 42.90 18.82 – 3.62 – 14.21
Including the cost of azithromycin and HSAs’ salaries
Cost/treatment (USD) 1.32 1.18 1.21 1.01 1.07 1.13
Cost per death averted (USD) 4,054.55 1797.54 – 348.74 – 1,366.63
Cost per DALY averted (USD) 45.05 19.97 – 3.87 – 15.18
HSA = health surveillance assistant.
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Generalizability of the effects of azithromycin MDA in Malawi
as an intervention for child health to other settings may be
possible to some extent depending on local child mortality
rate, child health interventions, and the as-yet undefined
mechanisms by which azithromycin MDA may reduce child
mortality.
Future evaluations regarding the cost-effectiveness of azi-
thromycinMDAfor reducingchildmortality shouldaimtoestimate
the cost-effectivenesswhen using the full economic cost. Further
understanding of the mechanism of action is required, and sub-
sequent analyses should assess the costs associated with tar-
geting the intervention in settings where it will be effective. A
further consideration is the potential for the development of
macrolide resistance and lower effectiveness with continued
biannualMDAasapossible consequence. Evidence from the
trachoma field indicates that although resistance (in nontarget
organisms) develops following azithromycin MDA, this usually
decreases to relatively low levels 6 months posttreatment.26,27
The levels of resistance do vary considerably by country,
however, and in Ethiopia, macrolide resistance in carried
Streptococcus pneumoniae has been reported at 20–30%
12–24 months post-cessation of MDA.28
Evidence from the MORDOR trial in Niger indicates mac-
rolide resistance in nasopharyngeal S. pneumoniae iso-
lates 6 months after the fourth biannual MDA was higher in
azithromycin-treated communities than placebo communi-
ties, although still at the relatively lowcommunitymean level of
12% macrolide resistance.29 Despite these low levels of re-
sistance, the effect size appeared to increase over the four
intercensal periods of the MORDOR trial, and indeed, with
continued treatment for a third year of biannual MDA in the
MORDOR II trial in Niger, effectiveness remained similar.30
This study assessed the cost-effectiveness per round of MDA
over the first 2 years of the intervention in Malawi, although
there is no evidence that the effect may decrease with sub-
sequent distributions in this setting.
In conclusion, these initial findings from the MORDOR trial
indicate that azithromycin MDA for reducing child mortality
has the potential to be a highly cost-effective intervention in
the Malawian setting, but that there is considerable variation
by geographical location. A greater understanding of the
reasons for geographical variation in effectiveness would be
desirable before wider implementation of the intervention.
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